Kite Pharma (NASDAQ: KITE) is researching a novel cancer-fighting approach that supercharges a patient’s immune system to better find and destroy cancer cells. Promising results in clinical trials are paving the way to a filing for Food and Drug Administration approval, and potentially, commercialization of its CAR-T therapy, and that’s causing investors to flock to this company’s stock.